{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:40Z","timestamp":1787026540535,"version":"build-2736575974"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Focal onset seizures, characterized by localized neuronal hyperexcitability in the brain, can be related to various structural, immune, genetic, or metabolic abnormalities. Autoimmune epilepsies are increasingly recognized. Neurochondrin antibody has been reported in a variety of rare autoimmune neurological disorders. This article aims to highlight the relevance of anti-neurochondrin in autoimmune epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a case presentation and literature review of autoimmune epilepsy associated with anti-neurochondrin antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 26-year-old African American right-handed man with a history of Sjogren\u2019s syndrome presented with near constant, rhythmic left-sided facial twitching movements, and one episode of generalized tonic clonic seizure. Magnetic resonance imaging (MRI) of the brain revealed borderline low volume right hippocampus. Cerebrospinal fluid (CSF) studies yielded elevated protein and mild lymphocytic pleocytosis. Antibody Prevalence in Epilepsy 2 (APE2) score was 6, and autoimmune workup was initiated. Anti-neurochondrin antibody returned positive in the CSF autoimmune encephalitis panel with a titer of 1:512 (Mayo Clinic TEST ID: ENC2). Seizures remained refractory to anti-seizure medications including divalproex, lacosamide, and oxcarbazepine. Immunotherapy with methylprednisolone and immunoglobulin improved his epileptic seizures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first reported case of refractory autoimmune epilepsy with positive CSF anti-neurochondrin antibody. This study contributes to the body of evidence supporting the role of neurochondrin antibody in epilepsy. Considering autoimmune testing in individuals with seizures having APE2 score &amp;gt; 4 can aid in timely diagnosis of immune-mediated epilepsy and initiation of immunotherapy, which can result in favorable clinical outcomes. Diagnosis of autoimmune epilepsy, in most cases, is based on clinical characteristics, MRI results, and CSF findings. In addition to the traditional antibody panel for autoimmune encephalitis, some novel antibodies, such as anti-neurochondrin, should also be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1459119","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:31:01Z","timestamp":1727051461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Refractory focal motor seizure associated with cerebrospinal fluid neurochondrin antibody"],"prefix":"10.3389","volume":"15","author":[{"given":"Rowaid","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Masel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030392","article-title":"Prevalence of neural autoantibodies in epilepsy of unknown etiology: systematic review and meta- analysis","volume":"11","author":"Cabezudo-Garc\u00eda","year":"2021","journal-title":"Brain Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01826-9","article-title":"Immune mechanisms in epileptogenesis: update on diagnosis and treatment of autoimmune epilepsy syndromes","volume":"83","author":"Flammer","year":"2023","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1212\/NXI.0000000000000612","article-title":"Neurochondrin neurological autoimmunity","volume":"6","author":"Shelly","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13311-019-00750-3","article-title":"Autoimmune epilepsy","volume":"16","author":"Husari","year":"2019","journal-title":"Neurotherapeutics: J Am Soc Exp Neurother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.879009","article-title":"Case report: alzheimer\u2019s dementia associated with cerebrospinal fluid neurochondrin autoantibodies","volume":"13","author":"Hansen","year":"2022","journal-title":"Front Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1212\/NXI.0000000000000307","article-title":"Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration","volume":"4","author":"Miske","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-019-01048-y","article-title":"Neurochondrin antibody serum positivity in three cases of autoimmune cerebellar ataxia","volume":"18","author":"Weihua","year":"2019","journal-title":"Cerebellum (London England)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15648","article-title":"Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia\u2014A case report and review of the literature","volume":"30","author":"Schwarzwald","year":"2023","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1606371","article-title":"Chorea minor associated with anti-neurochondrin autoantibodies","volume":"48","author":"Rommel","year":"2017","journal-title":"Neuropediatrics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414033200","article-title":"Neurochondrin negatively regulates CaMKII phosphorylation, and nervous system-specific gene disruption results in epileptic seizure","volume":"280","author":"Dateki","year":"2005","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1178496","article-title":"Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling","volume":"326","author":"Wang","year":"2009","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S136723","article-title":"Clinical features of limbic encephalitis with LGI1 antibody","volume":"13","author":"Wang","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1550059415595907","article-title":"Are there any specific EEG findings in autoimmune epilepsies","volume":"47","author":"Baysal-Kirac","year":"2016","journal-title":"Clin EEG Neurosci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14649","article-title":"Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability","volume":"60","author":"Dubey","year":"2019","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1212\/NXI.0000000000000353","article-title":"Antiepileptic drug therapy in patients with autoimmune epilepsy","volume":"4","author":"Feyissa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1459119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:31:02Z","timestamp":1727051462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1459119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2024.1459119"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1459119","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1459119"}}